In FY11, the industry recorded revenues worth US$ 3.6 billion, registering a y-o-y growth of 20 per cent over FY10. The industry is expected to grow significantly to US$ 11.6 billion by 2017, driven by various Government initiatives.
The bio-pharmaceutical sector accounted for the largest chunk of the biotech industry, with a share of 61.7 per cent in total revenues. Bio-services and the bio-agri segments followed the bio-pharmaceutical segment with a share of 18.8 per cent and 14.4 per cent respectively, in FY11.
Domestic bio-services sector record a growth of 96.8 per cent in FY11 followed by bio-agri (28.1 per cent) and bio-pharma (25.8 per cent), respectively. Bio-informatics export revenue recorded a growth of 43.4 per cent in FY11 followed by bio-industrial (28.1 per cent) and bio-pharma (21.1 per cent), respectively.
Revenues from biotech exports were valued at USD1.8 billion in 2010–11, constituting 52 per cent of the biotech industry’s revenue. Export revenue from biotech grew by compound annual rate of 18.7 per cent over 2007-10. Bio-pharma contributes maximum to export earning followed by bio-services.
India is amongst the top 12 biotech destinations in the world and second in Asia, after China. India is also the largest producer of recombinant Hepatitis B vaccine in the world.
Click here to Download File (Size: 4.35 MB )